Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellgram-CLI in Critical Limb Ischemia
NCT02477540Phase 1Withdrawn
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Bone Marrow MSCs
01
Overview
Phase 1, open-label, single-arm trial of Cellgram-CLI in critical limb ischemia (CLI), sponsored by Pharmicell Co., Ltd. Primary endpoint: Ankle Brachial Pressure Index at 6 months. Planned start Dec 2019; status: withdrawn.
02
Drugs
Cellgram-CLI
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02477540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477540.